Newly available antibodies with practical applications in surgical pathology

International Journal of Surgical Pathology

Volumn 21, Issue 6, 2013, Pages 553-572

  Chan, John K C ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

ALK; antibodies; Arginase 1; DOG1; ERG; immunohistochemistry; Langerin; MUC4; Napsin A; OCT3 4; PAX8; SALL4; SOX10; SOX11; succinate dehydrogenase; SV40; Treponema pallidum

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIBODY; ARGINASE; ARGINASE A; BIOLOGICAL MARKER; LANGERIN; MUCIN 4; NAPSIN A; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN DOG1; PROTEIN SALL4; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR SOX11; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ALK GENE; BK VIRUS INFECTION; CELL DIFFERENTIATION; ENDOTHELIUM; FIBROMYXOID SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE TRANSLOCATION; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LANGERHANS CELL; LIVER TUMOR; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MANTLE CELL LYMPHOMA; MELANOCYTE; NONHUMAN; ONCOGENE; PARAGANGLIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SARCOMA; SCHWANN CELL; SENSITIVITY AND SPECIFICITY; SIMIAN VIRUS 40; SYPHILIS; TREPONEMA PALLIDUM; VASCULAR TUMOR; YOLK SAC TUMOR;

ALK; ANTIBODIES; ARGINASE 1; DOG1; ERG; IMMUNOHISTOCHEMISTRY; LANGERIN; MUC4; NAPSIN A; OCT3/4; PAX8; SALL4; SOX10; SOX11; SUCCINATE DEHYDROGENASE; SV40; TREPONEMA PALLIDUM;

ANTIBODIES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PATHOLOGY, SURGICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84887894091     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896913507601     Document Type: Review

References (97)

1. Chan JK, Ip YT, Cheuk W. The utility of immunohistochemistry for providing genetic information on tumors.. Int J Surg Pathol. 2013 ; 21: 455-475
2. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008 ; 32: 1566-1571
3. Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic Mullerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011 ; 35: 1837-1847
4. Tong GX, Memeo L, Colarossi C, et al. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol. 2011 ; 35: 1473-1483
5. Weissferdt A, Moran CA. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am J Surg Pathol. 2011 ; 35: 1305-1310
6. Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010 ; 34: 723-729
7. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol. 2012 ; 25: 231-236
8. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008 ; 21: 192-200
9. Hu Y, Hartmann A, Stoehr C, et al. PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol. 2012 ; 65: 254-256
10. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011 ; 35: 816-826
11. Albadine R, Schultz L, Illei P, et al. PAX8 (+)/p63(-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010 ; 34: 965-969
12. Tong GX, Weeden EM, Hamele-Bena D, et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?. Am J Surg Pathol. 2008 ; 32: 1380-1387
13. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010 ; 34: 627-635
14. Kenny SL, McBride HA, Jamison J, McCluggage WG. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-beta. Am J Surg Pathol. 2012 ; 36: 799-807
15. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010 ; 41: 20-25
16. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012 ; 136: 163-171
17. Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012 ; 136: 155-162
18. Ordonez NG. A word of caution regarding napsin A expression in squamous cell carcinomas of the lung. Am J Surg Pathol. 2012 ; 36: 396-401
19. Xu B, Abourbih S, Sircar K, et al. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases. Appl Immunohistochem Mol Morphol. In press ;:
20. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010 ; 34: 1147-1154
21. Krings G, Ramachandran R, Jain D, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 2013 ; 26: 782-791
22. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008 ; 111: 3498-3506
23. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011 ; 35: 432-441
24. Yaskiv O, Rubin BP, He H, Falzarano S, Magi-Galluzzi C, Zhou M. ERG protein expression in human tumors detected with a rabbit monoclonal antibody. Am J Clin Pathol. 2012 ; 138: 803-810
25. McKay KM, Doyle LA, Lazar AJ, Hornick JL. Expression of ERG, an Ets family transcription factor, distinguishes cutaneous angiosarcoma from histological mimics. Histopathology. 2012 ; 61: 989-991
26. Minner S, Luebke AM, Kluth M, et al. High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers. Histopathology. 2012 ; 61: 445-453
27. Miettinen M, Wang Z, Sarlomo-Rikala M, Abdullaev Z, Pack SD, Fetsch JF. ERG expression in epithelioid sarcoma: a diagnostic pitfall. Am J Surg Pathol. 2013 ; 37: 1580-1585
28. Tomlins SA, Palanisamy N, Brenner JC, et al. Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol. 2013 ; 139: 771-779
29. Verdu M, Trias I, Roman R, et al. ERG expression and prostatic adenocarcinoma. Virchows Arch. 2013 ; 462: 639-644
30. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011 ; 24: 1128-1138
31. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011 ; 35: 1014-1020
32. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011 ; 459: 441-447
33. Shah RB. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv Anat Pathol. 2013 ; 20: 117-124
34. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010 ; 12: 590-598
35. Ordonez NG. Value of SOX10 immunostaining in tumor diagnosis. Adv Anat Pathol. 2013 ; 20: 275-283
36. Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012 ; 20: 445-450
37. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-Schwannian and melanocytic marker. Am J Surg Pathol. 2008 ; 32: 1291-1298
38. Ohtomo R, Mori T, Shibata S, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol. In press ;:
39. Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol. :
40. Shin J, Vincent JG, Cuda JD, et al. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. J Am Acad Dermatol. 2012 ; 67: 717-726
41. Cimino-Mathews A, Subhawong AP, Elwood H, et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol. 2013 ; 44: 959-965
42. Tsuta K, Raso MG, Kalhor N, Liu DC, Wistuba II, Moran CA. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology. 2011 ; 58: 276-285
43. Jennings C, Kim J. Identification of nodal metastases in melanoma using sox-10. Am J Dermatopathol. 2011 ; 33: 474-482
44. Blochin E, Nonaka D. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology. 2009 ; 55: 626-628
45. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004 ; 165: 107-113
46. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009 ; 33: 1401-1408
47. Chenevert J, Duvvuri U, Chiosea S, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012 ; 25: 919-929
48. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008 ; 32: 210-218
49. Lopes LF, West RB, Bacchi LM, van de Rijn M, Bacchi CE. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): Comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol. 2010 ; 18: 333-337
50. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009 ; 33: 437-446
51. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012 ; 72: 5307-5316
52. Hemminger J, Iwenofu OH. Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms. Histopathology. 2012 ; 61: 170-177
53. de Jong J, Stoop H, Dohle GR, et al. Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol. 2005 ; 206: 242-249
54. Cao D, Li J, Guo CC, Allan RW, Humphrey PA. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol. 2009 ; 33: 1065-1077
55. Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010 ; 34: 533-540
56. Liu A, Cheng L, Du J, et al. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol. 2010 ; 34: 697-706
57. Cao D, Guo S, Allan RW, Molberg KH, Peng Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009 ; 33: 894-904
58. Wang F, Liu A, Peng Y, et al. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol. 2009 ; 33: 1529-1539
59. Gopalan A, Dhall D, Olgac S, et al. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol. 2009 ; 22: 1066-1074
60. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol. 2004 ; 28: 935-940
61. Preda O, Nicolae A, Aneiros-Fernandez J, Borda A, Nogales FF. Glypican 3 is a sensitive, but not a specific, marker for the diagnosis of yolk sac tumours. Histopathology. 2011 ; 58: 312-314
62. Hattab EM, Tu PH, Wilson JD, Cheng L. OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. Am J Surg Pathol. 2005 ; 29: 368-371
63. Mao TL, Kurman RJ, Huang CC, Lin MC, Shih Ie M. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol. 2007 ; 31: 1726-1732
64. Doyle LA, Moller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011 ; 35: 733-741
65. Llinares K, Escande F, Aubert S, et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol. 2004 ; 17: 150-157
66. Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol. 2004 ; 7: 607-614
67. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008 ; 32: 615-619
68. Rezk SA, Spagnolo DV, Brynes RK, Weiss LM. Indeterminate cell tumor: a rare dendritic neoplasm. Am J Surg Pathol. 2008 ; 32: 1868-1876
69. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008 ; 111: 800-805
70. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009 ; 94: 1555-1562
71. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol. 2010 ; 23: 105-112
72. Nordstrom L, Andreasson U, Jerkeman M, Dictor M, Borrebaeck C, Ek S. Expanded clinical and experimental use of SOX11 - using a monoclonal antibody. BMC Cancer. 2012 ; 12: 269
73. Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica. 2009 ; 94: 1563-1568
74. Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology. 2012 ; 61: 685-693
75. Martin-Ezquerra G, Fernandez-Casado A, Barco D, et al. Treponema pallidum distribution patterns in mucocutaneous lesions of primary and secondary syphilis: an immunohistochemical and ultrastructural study. Hum Pathol. 2009 ; 40: 624-630
76. Facchetti F, Incardona P, Lonardi S, et al. Nodal inflammatory pseudotumor caused by luetic infection. Am J Surg Pathol. 2009 ; 33: 447-453
77. Latif S, Zaman F, Veeramachaneni R, et al. BK polyomavirus in renal transplants: role of electron microscopy and immunostaining in detecting early infection. Ultrastruct Pathol. 2007 ; 31: 199-207
78. Sunden Y, Suzuki T, Orba Y, et al. Characterization and application of polyclonal antibodies that specifically recognize JC virus large T antigen. Acta Neuropathol. 2006 ; 111: 379-387
79. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 ; 137: 828-860
80. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013 ; 8: 45-51
81. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009 ; 15: 3143-3149
82. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010 ; 16: 1561-1571
83. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. In press ;:
84. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 2013 ; 8: 322-328
85. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011 ; 6: 1359-1366
86. Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011 ; 96: E1472 - E1476
87. Hensen EF, Bayley JP. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer. 2011 ; 10: 355-363
88. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology. 2012 ; 44: 285-292
89. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009 ; 10: 764-771
90. Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010 ; 41: 805-814
91. Gill AJ, Chou A, Vilain R, et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol. 2010 ; 34: 636-644
92. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011 ; 35: 1712-1721
93. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 ; 108: 314-318
94. Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol. 2011 ; 35: 495-504
95. Gaal J, Stratakis CA, Carney JA, et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol. 2011 ; 24: 147-151
96. Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013 ; 37: 234-240
97. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol. 2013 ; 26: 289-294